Ora Biomedical and the Rapamycin Longevity Lab have launched a project to screen more than 600 mTOR inhibitors in the hope of finding some that are superior to geroscience’s poster child, rapamycin.
5 Likes
What about Everolimus? shorter half-life and easier to cross BBB.
1 Like